Eli Lilly Retatrutide Outperforms Ozempic in Landmark Trial; Fed Holds Rates Steady
· thestockmarketwatch.com
Eli Lilly (LLY) announced today that its next-generation obesity treatment, retatrutide, significantly outperformed Novo Nordisk’s (NVO) Ozempic in the
This update was written automatically with AI from market data and news wire reports, and published without review by a person.
Key Takeaways
Eli Lilly (LLY) ...